Drug Profile
Research programme: drug discovery - Simcere Pharmaceutical Group/Suzhou NeuPharma
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Simcere Pharmaceutical Group; Suzhou NeuPharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in China
- 31 Oct 2011 Early research in Cancer in China (unspecified route)